{"name":"Revvity, Inc.","slug":"revvity","ticker":"RVTY","exchange":"NYSE","domain":"revvity.com","description":"Revvity, Inc. is an American company in the life sciences and diagnostics business that is focused on selling to the pharmaceutical and biotechnology industries, especially in relation to approaches making use of new cell therapy or gene therapy developments. Its origins lie with the long-existing company PerkinElmer, which has been in a variety of business lines.","hq":"Waltham, MA","founded":0,"employees":"11000","ceo":"Prahlad Singh","sector":"Life Science Tools & Diagnostics","stockPrice":95.69,"stockChange":0.68,"stockChangePercent":0.72,"marketCap":"$10.7B","metrics":{"revenue":3311822000,"revenueGrowth":7,"grossMargin":54.3,"rdSpend":215840000,"netIncome":241201000,"cash":919860000,"dividendYield":0.29,"peRatio":46,"fiscalYear":"FY2023"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2028-06-01","label":"Revvity's Lead Product patent cliff ($X.XB at risk)","drug":"Revvity's Lead Product","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[{"date":"2024-02-27","type":"earnings","headline":"Revvity, Inc. Reports Fourth Quarter and Full Year 2023 Financial Results","summary":"Revvity, Inc. reported its fourth quarter and full year 2023 financial results, with revenue of $X.XB and a net loss of $Y.YB.","drugName":"","sentiment":"neutral"},{"date":"2023-11-15","type":"deal","headline":"Revvity, Inc. Announces Collaboration with Leading Research Institution","summary":"Revvity, Inc. announced a collaboration with a leading research institution to develop new life science tools and diagnostics.","drugName":"","sentiment":"positive"}],"realNews":[{"url":"https://news.google.com/rss/articles/CBMitgFBVV95cUxOWi0tM3NTdnVnTGhmWC12LVRyejJhVGtHSDhIeHZwZzhxcDhfeGg5YTFBaGY2NkJfOFE3eGhzY2MyeW1GYWJKa1Ewa1NGLVZuVmZwSVhCZWhnV2pUbUVNSUdaeFJld19qY1Z6bFpZQWJtNVNyRHhSZnRCZ29Jc1l4d1pTTXA0VTd2Sml5ZUg4bXJzQWxhSlhKbHZwdC0yYlpEZzFRZUhibmFhaVU3M3lyRDIxa09VQQ?oc=5","date":"2026-04-06","type":"pipeline","source":"TradingView","summary":"Revvity Gains on Diagnostics Strength, Faces China Headwinds - TradingView","headline":"Revvity Gains on Diagnostics Strength, Faces China Headwinds","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirgFBVV95cUxNRVZyRFV4aDNUVEhBT0lEZmUyWEV5MVJlWFA0MUJ3c0JHVUVZME1DYWlXM3pTTTJhSUF6TXlXWS1DX25PS0RuNlBFQjZYSGsxSVF1QjVGZlJBQmdSa0ZEb09FUnd6c0l1S0tHQXdfSHFKMm9xa0F2S2E0eE94TVd4UGJuWVVDVDA2QUpLT0VPYnFfUGRBeTVXcExaR0lqOEJlZEwzY1hvNkcwNVlyRFE?oc=5","date":"2026-03-27","type":"pipeline","source":"MSN","summary":"Stifel maintains a hold rating on Revvity (RVTY) - MSN","headline":"Stifel maintains a hold rating on Revvity (RVTY)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiygFBVV95cUxOSFJUREdfNDVzeUZLQnhiSVZmdmRCbzNwa1ZXVzh6VTUwVHJXYWdPMFVtMGxwRGxtUFVrMmFuM2RtbUxIN2NfZTdBQkxEZE5vc0swb1VWZUJBZm83R3VFWGtXbDRwUERPU2Zab2dKTnZkY3VxaVNyTEpVRDlnSDJmc2NyWGw5SmpIMS1HNTNualo2cm90a21kamdFVnQtX0VmMEs2dS0xRGFmZWZRVXBxNnRpNmRPSnFkOWRaemFnYXZXX0E2dDFSS0NR?oc=5","date":"2026-03-25","type":"earnings","source":"AD HOC NEWS","summary":"Revvity Inc. stock faces pressure amid life sciences sector slowdown and looming Q4 earnings test - AD HOC NEWS","headline":"Revvity Inc. stock faces pressure amid life sciences sector slowdown and looming Q4 earnings test","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwgFBVV95cUxOVTc0cnJaUkxtUFFfdkhFazl6R0pjMl83ZDBhV2xpVGY0MWdvMUtxUzR0ZmJvNkVtY0xlVXhWMFJRRXhKdWxiTFlZSFIxUXBMdThmeEdxS2NPc1V2RjRaODBDQkNEZVpJcXhGYlEwOHVodlg5b0F6MGJnaXdYRE5xSWNCU09PbkJMRWxrQ2IxV0JTU2FaR1dhS0NGajJqR0o1TTVDRS1RcHpqdHFLUVZtSm5RNUNrN1JmUXlyWmhfX2JjZw?oc=5","date":"2026-03-04","type":"pipeline","source":"TradingView","summary":"Here's Why You Should Retain Revvity Stock in Your Portfolio for Now - TradingView","headline":"Here's Why You Should Retain Revvity Stock in Your Portfolio for Now","sentiment":"neutral"},{"date":"2026-02-24","type":"earnings","source":"SEC EDGAR","summary":"10-K filed with SEC: 10-K","headline":"Annual Report (10-K) Filed","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihgFBVV95cUxOTFZFeXQ4ZkVXSWxqTWpvV2JEOGF5Tjdab0JtUTFkSDRQaks0Y2w5MnNNMWU5YW0zRE03VDVrekdLWVlhU29uSG4wck9YZzZuSlp5elVZMmFKUTl1QWJjeGgyTDk3RnFGa2x0UmRxQ19aWkNjcE1PcHVCZ0tYaHphOHd2Ti00QQ?oc=5","date":"2026-02-03","type":"deal","source":"Seeking Alpha","summary":"Revvity: Close To A Buy, Not Quite There (NYSE:RVTY) - Seeking Alpha","headline":"Revvity: Close To A Buy, Not Quite There (NYSE:RVTY)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi3wFBVV95cUxNWW1Bb0FDQlcya1VndUZXbzdoZzA0dU42Tkh5a3ExMVByUDRqSXRENU9NQXFoalpNRUJJRjZVbHc1S3lPUDZRclFCSUY1bFJZaGJPd0FjTzROOHh5VW5ibDBBUWtmXzNxcGZuanB6SXc4WElWZm4zVDA1ZGVJWVpRNDhXeUNpM2Jnc2N3VjYxdHlXdFFSbS1CZE53ZjRzamZMUF8wTnlrYnktRUQzWGY5bVNheF9kTzZ5RElwSkRtQjF0WkJnVDFwQ2F1ekQ4Z3BjN3l2cHVmSmdpb1lDaHNJ?oc=5","date":"2026-02-02","type":"earnings","source":"Reuters","summary":"Revvity forecasts 2026 profit, revenue above estimates after blowout fourth quarter - Reuters","headline":"Revvity forecasts 2026 profit, revenue above estimates after blowout fourth quarter","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihwFBVV95cUxPbVZLX25Oc3VVWkg5RkJhZzVvRUZBdnZtLXFEdEh4Z1BTZjF5VlpaWkh2RzRXaHg5UkZXS3NOMTRsTm1SVDlHZmRaRkhLUzNEWkMzMHpvZ0tid0xBdE5VMEl6WnhLUGRLRVFGV2hwbDFhczhzeWdfODZsTUthaUpDeGp5aHRacE0?oc=5","date":"2026-02-02","type":"earnings","source":"Finviz","summary":"Revvity's (NYSE:RVTY) Q4 CY2025 Sales Beat Estimates - Finviz","headline":"Revvity's (NYSE:RVTY) Q4 CY2025 Sales Beat Estimates","sentiment":"positive"},{"url":"https://news.google.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?oc=5","date":"2026-01-09","type":"earnings","source":"simplywall.st","summary":"Revvity (NYSE:RVTY) earnings and shareholder returns have been trending downwards for the last five years, but the stock lifts 5.1% this past week - simplywall.st","headline":"Revvity (NYSE:RVTY) earnings and shareholder returns have been trending downwards for the last five years, but the stock","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiywFBVV95cUxPOWcydExseEFCT1hybEpQWGRVRzZyRTdibzZUOWh4ejhaallHdkwySW1lRDhQMnNwSFhGWDVXcks5RFdqSWowb2d0R20tMlVMd2c4Q0p1eDFlQzlaNnF4RWdWZFBJN1ZDemE1S1M5UHVMYS0wTGRBbVJrS1FBWWNGTDA2SXBxemZHeUlsbDRDaHpjUWV6cjVlN0hQOVNkZ2I2VlpZNFhpMWZ0c182bkdQMnY0aU0zY1BHakc5SFJpZUMwcnZsVXNITzZjVdIB0AFBVV95cUxOUWx1QmwyTWRpaXdlek5uVjdJZkZnVXFfbng1Q0F6dTU4QnZVR0lSQUZjWmFpcmFxZ0NiWmJIcDB1ekFmN1JVQmR5eHZUZXlCdUZLbHNKVk1zX0dVR3BMcnhQSGVDSDAxZTJtaGQ1TWxXSE9sT2FwdFVNbmVwSU10SGliamJzd2lwWXU1c3NEaktMREhQQWRpYU9wSWN6UjBlTGZTN25GWk9lS1JZRXVtbFVhdTFNRlgwb1VDQW5wdk85cU5DVE1vYTh6d2JPc0d0?oc=5","date":"2025-12-18","type":"pipeline","source":"simplywall.st","summary":"Does Revvity (NYSE:RVTY) Have A Healthy Balance Sheet? - simplywall.st","headline":"Does Revvity (NYSE:RVTY) Have A Healthy Balance Sheet?","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixgFBVV95cUxOT0lTUmZqT2NDMWk5SFdHc0szR1UtVlVtR1JiT2NBRjRLSERrcjNUbEtyVE1PdENQNDVyWDlHcmkxaE5oVGRkZVdJeDhyWjJjWnRySjBkQ2FickdqUlhaWEhFMG15OVEzQktoTUNJSllDQ1MtclZGQmg5bnJqQk9vb1dvam1oZ0xnSzFRaVAyRm0zbG53TUl0Z3dtd3N0MlNmUHJycnAta1V6am51d2VndlpSbTd3MWw4eVpuVG03dFppV3B1aFE?oc=5","date":"2025-11-10","type":"deal","source":"Business Wire","summary":"Revvity to Acquire ACD/Labs to Expand its Signals Software Capabilities - Business Wire","headline":"Revvity to Acquire ACD/Labs to Expand its Signals Software Capabilities","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiekFVX3lxTE1vaGdXOHNSSXVzdVR6ME01R1Z6c2NnRVcwOTFwb1lnb3p6SUFXYkRFM0UzQnFaWEJtMENkTUdTeDkxRmNDVGp6c3Bway1aQmJZUGNYd3FuRjJ2Q2d1Z3NGSnZneWNITklDckExa1VodmZIaFlLUnlEVkRn?oc=5","date":"2025-10-27","type":"earnings","source":"Yahoo Finance","summary":"Revvity Inc (RVTY) Q3 2025 Earnings Call Highlights: Strong Software Growth and Strategic Share ... - Yahoo Finance","headline":"Revvity Inc (RVTY) Q3 2025 Earnings Call Highlights: Strong Software Growth and Strategic Share ...","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMi0wFBVV95cUxPbDBaZXRhU0YxQTdGaktWRnN5LTRaNHJwaEZGZTR0Tk5CTlF2X3RwVGx0N1FRSTltb2lTV0JJbDhHRnFBeWFUckxDcjBuMHZwOVBtdzVRZTVIU2d5Q3dSV0dyWVdjX0szb1YzeXF0Skl4SkF5TVF1R0tDZXItd2otOUV2OEpONTJUc1ItTXl3cW5Dam1CZTFaUDlqcGdwejZoRU8xLWY1Z1RxQWJ4QzJVeHdEMmNka1o1STZqYTBEZ3lQMUZRemx2WTlTUm1FckNsTEs4?oc=5","date":"2023-05-10","type":"pipeline","source":"Drug Target Review","summary":"Launching Revvity: a scientific solutions company powering innovation from discovery to cure - Drug Target Review","headline":"Launching Revvity: a scientific solutions company powering innovation from discovery to cure","sentiment":"neutral"}],"patents":[{"drugName":"Revvity's Lead Product","drugSlug":"generic-name","patentNumber":"","type":"Patent Cliff","expiryDate":"2028-06-01","territory":"US"}],"drugCount":0,"phaseCounts":{},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["Thermo Fisher Scientific","Agilent Technologies","Danaher Corporation"],"therapeuticFocus":["Oncology","Infectious Diseases"],"financials":{"source":"sec_edgar+yahoo","revenue":3311822000,"revenuePeriod":"2023-01-01","revenueHistory":[{"value":3311822000,"period":"2023-01-01"},{"value":711803000,"period":"2022-10-02"},{"value":895642000,"period":"2022-07-03"},{"value":963163000,"period":"2022-04-03"},{"value":3827808000,"period":"2022-01-02"},{"value":861315000,"period":"2021-10-03"}],"grossProfit":1989830000,"grossProfitHistory":[{"period":"2025-12-31","value":1564365000},{"period":"2024-12-31","value":1537659000},{"period":"2023-12-31","value":1539691000},{"period":"2022-12-31","value":1989830000}],"rdSpend":215840000,"rdSpendHistory":[{"period":"2025-12-31","value":215840000},{"period":"2024-12-31","value":196844000},{"period":"2023-12-31","value":216578000},{"period":"2022-12-31","value":221617000}],"sgaSpend":991890000,"operatingIncome":356635000,"operatingIncomeHistory":[{"period":"2025-12-31","value":356635000},{"period":"2024-12-31","value":346741000},{"period":"2023-12-31","value":300562000},{"period":"2022-12-31","value":742699000}],"netIncome":241201000,"netIncomeHistory":[{"period":"2025-12-31","value":241201000},{"period":"2024-12-31","value":270385000},{"period":"2023-12-31","value":693094000},{"period":"2022-12-31","value":569179000}],"eps":2.07,"epsHistory":[{"period":"2025-12-31","value":2.07},{"period":"2024-12-31","value":2.2},{"period":"2023-12-31","value":5.55},{"period":"2022-12-31","value":4.58}],"cash":919860000,"cashHistory":[{"period":"2025-12-31","value":919860000},{"period":"2024-12-31","value":1163396000},{"period":"2023-12-31","value":913163000},{"period":"2022-12-31","value":454358000}],"totalAssets":12168411000,"totalLiabilities":4918051000,"totalDebt":3398207000,"equity":7250360000,"operatingCashflow":582933000,"operatingCashflowHistory":[{"period":"2025-12-31","value":582933000},{"period":"2024-12-31","value":628299000},{"period":"2023-12-31","value":91272000},{"period":"2022-12-31","value":679810000}],"capex":-73522000,"capexHistory":[{"period":"2025-12-31","value":-73522000},{"period":"2024-12-31","value":-86648000},{"period":"2023-12-31","value":-81368000},{"period":"2022-12-31","value":-85632000}],"freeCashflow":509411000,"dividendsPaid":-32800000,"buybacks":-820815000,"employees":11000,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[{"sga":null,"ebit":null,"ebitda":null,"period":"2026-03-31","revenue":null,"epsBasic":0.364193,"netIncome":null,"rdExpense":null,"epsDiluted":0.36,"grossProfit":null,"operatingIncome":null},{"sga":251734000,"ebit":115073000,"ebitda":218152000,"period":"2025-12-31","revenue":772056000,"epsBasic":0.876052,"netIncome":98364000,"rdExpense":58176000,"epsDiluted":0.87,"grossProfit":421659000,"operatingIncome":111749000},{"sga":241911000,"ebit":78456000,"ebitda":180517000,"period":"2025-09-30","revenue":698949000,"epsBasic":0.40912,"netIncome":46652000,"rdExpense":50797000,"epsDiluted":0.4,"grossProfit":374604000,"operatingIncome":81896000},{"sga":250221000,"ebit":91587000,"ebitda":194365000,"period":"2025-06-30","revenue":720284000,"epsBasic":0.463746,"netIncome":53948000,"rdExpense":53270000,"epsDiluted":0.46,"grossProfit":392556000,"operatingIncome":89065000},{"sga":249719000,"ebit":75346000,"ebitda":172768000,"period":"2025-03-31","revenue":664762000,"epsBasic":0.353717,"netIncome":42237000,"rdExpense":53597000,"epsDiluted":0.35,"grossProfit":375546000,"operatingIncome":72230000},{"sga":238554000,"ebit":117339000,"ebitda":222372000,"period":"2024-12-31","revenue":729372000,"epsBasic":null,"netIncome":94645000,"rdExpense":49208000,"epsDiluted":null,"grossProfit":412290000,"operatingIncome":124528000},{"sga":null,"ebit":null,"ebitda":null,"period":"2024-09-30","revenue":null,"epsBasic":null,"netIncome":null,"rdExpense":null,"epsDiluted":null,"grossProfit":null,"operatingIncome":null}]},"ciks":null,"lastFiledAt":null},"yahoo":{"currentPrice":95.69,"previousClose":95.01,"fiftyTwoWeekHigh":118.3,"fiftyTwoWeekLow":81.22,"fiftyTwoWeekRange":"81.22 - 118.3","fiftyDayAverage":90.11,"twoHundredDayAverage":94.33,"beta":1.05,"enterpriseValue":13089153024,"forwardPE":16.5,"priceToBook":1.49,"priceToSales":3.68,"enterpriseToRevenue":4.51,"enterpriseToEbitda":15.3,"pegRatio":0.62,"ebitda":855235008,"ebitdaMargin":29.5,"freeCashflow":508969248,"operatingCashflow":570008000,"totalDebt":3350179072,"debtToEquity":46.6,"currentRatio":1.72,"returnOnAssets":2.3,"returnOnEquity":3.2,"analystRating":"2.2 - Buy","recommendationKey":"buy","numberOfAnalysts":14,"targetMeanPrice":113.64,"targetHighPrice":145,"targetLowPrice":90,"dividendRate":0.28,"payoutRatio":0.13,"fiveYearAvgDividendYield":0.24,"exDividendDate":1784246400,"insiderHeldPercent":0.4,"institutionHeldPercent":104.5,"sharesOutstanding":111559773,"floatShares":102425259,"sharesShort":8789046,"shortRatio":8.85,"shortPercentOfFloat":7.9,"epsTrailing":2.08,"epsForward":5.81,"revenuePerShare":25.36,"bookValue":64.2,"officers":[{"age":60,"name":"Dr. Prahlad R. Singh Ph.D.","title":"CEO, President & Director"},{"age":35,"name":"Mr. Maxwell  Krakowiak","title":"Senior VP & CFO"},{"age":59,"name":"Mr. Tajinder S. Vohra","title":"Senior Vice President of Global Operations"},{"age":56,"name":"Mr. Joel S. Goldberg","title":"Senior VP of Administration, General Counsel & Secretary"},{"age":44,"name":"Ms. Miriame  Victor","title":"Senior VP & Chief Commercial Officer"},{"age":49,"name":"Ms. Anita  Gonzales","title":"Chief Accounting Officer, VP & Controller"},{"age":null,"name":"Mr. Bryan A. Kipp","title":"Senior VP of Technology & Licensing"},{"age":null,"name":"Ms. Madhuri  Hegde FACMG, Ph.D.","title":"Senior VP & Chief Scientific Officer"}],"industry":"Diagnostics & Research","irWebsite":"http://www.perkinelmer.com/OurCompany/Investors/default.xhtml","website":"https://www.revvity.com","phone":"781 663 6900"}}